• 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 喝了6瓶劲酒和1斤白酒 男子手持钢锯在重庆西站撒泼遭控制 2019-06-01
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>公司动态>Covidien公司将以26亿美元现金收购医用血管设备制造商ev3公司(EVVV)

    时时彩平台出租: Covidien公司将以26亿美元现金收购医用血管设备制造商ev3公司(EVVV)

    Covidien2010年6月2日 11:33 点击:4101

    时时彩网络平台 www.qlgr.net

    美国Covidien  美国ev3
    药物和医疗设备制造商Covidien公司(COV)周二宣布,将以26亿美元现金出价,收购医用血管设备制造商ev3公司(EVVV)。

    报道称,Covidien公司计划以每股22.50美元收购ev3所有流通股,按照ev3上周五收盘价计算,溢价约19%。ev3公司主要生产用于血管内手术的医用设备,以及其他神经血管设备和心脏支架,球囊导管等。公司预计今年的收入能达到5.2亿美元到5.3亿美元。

    双方董事会已经批准了相关交易,ev3的大股东也已经表示将支持这项交易。Convidien公司表示,一旦获得监管机构同意,交易将于今年7月31日之前完成。
     

    Covidien Announces Definitive Agreement to Acquire ev3 Inc.
    • Adds significant scale to vascular platform with strong market positions
    • Provides broad product portfolio and robust pipeline in high-growth market segments
    • Leverages global infrastructure, physician education and training expertise

    DUBLIN & PLYMOUTH, Minn., Jun 01, 2010 (BUSINESS WIRE) --Covidien plc (NYSE:COV) and ev3 Inc. (NASDAQ:EVVV) today announced that they have signed a definitive merger agreement under which Covidien will acquire all of the outstanding shares of ev3 Inc. for $22.50 per share in cash, for a total of $2.6 billion, net of cash acquired. This transaction further accelerates Covidien's strategy of building a world-class vascular platform addressing high-growth markets and positions Covidien to become a leading endovascular player, with strong positions in both the peripheral vascular and neurovascular markets.

    "The acquisition of ev3 will enable Covidien to significantly expand its presence in the vascular market and is in line with our strategy of becoming a leading partner with vascular surgeons, neurosurgeons, interventional cardiologists and interventional radiologists," said Richard J. Meelia, Chairman, President and CEO of Covidien. "With its broad product portfolio, clinical expertise and call-point synergies with our existing vascular franchise, ev3 will be an important addition to our innovative vascular intervention products."

    "We believe this transaction will provide truly unique opportunities and will create value for both companies' stockholders, patients and employees," said Robert Palmisano, President and CEO of ev3. "We will be able to advance our broad platform of peripheral vascular and neurovascular technologies with a leading global healthcare products company that shares our vision of delivering breakthrough and innovative medical solutions for improved patient outcomes. In addition, this combination will provide the opportunity for further innovation to support endovascular market growth and procedure penetration worldwide, while our employees will be afforded the opportunity to be part of a larger organization with greater depth of resources for sustained success in our industry."

    ev3 Inc. is dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of peripheral vascular and neurovascular diseases. ev3 offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today: peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, flow diversion, thrombectomy catheters and occlusion balloons.

    Financial Highlights

    Under the terms of the agreement, Covidien will pay $22.50 in cash per ev3 share for a total of approximately $2.6 billion, net of cash acquired. The combination with ev3 will provide an additional growth platform for Covidien and is expected to be accretive to both revenue and earnings growth rates.

    The transaction, which will take the form of an all-cash tender offer by a wholly-owned subsidiary of Covidien, followed by a second-step merger, is subject to customary closing conditions, including receipt of certain regulatory approvals, and is expected to be completed by July 31, 2010. The Boards of Directors of both companies have unanimously approved the transaction. All of the directors and executive officers of ev3 have confirmed their intention to tender all shares held by them into the offer, and certain stockholders affiliated with Warburg, Pincus Equity Partners LP, holding approximately 24% of ev3's outstanding common stock, have entered into agreements with Covidien to tender their shares. Once the transaction has been completed, Covidien will report ev3 as part of its Vascular Products line in the Medical Devices business segment.

    Assuming a closing on July 31, 2010, Covidien expects that this transaction, on a GAAP basis, will dilute 2010 and 2011 earnings per share. On a Non-GAAP basis, excluding transaction, restructuring and other costs, Covidien expects this transaction to dilute fiscal 2010 earnings per share by 5 to 8 cents; however, the underlying strength of Covidien's existing businesses is expected to offset a portion of this dilution. Covidien expects fiscal 2011 Non-GAAP earnings per share to be diluted by approximately 10 to 15 cents, primarily due to higher depreciation/amortization, interest and income tax expenses.

    Covidien intends to finance the transaction through a combination of cash on hand, commercial paper and a fully committed bridge facility.

    Covidien will hold a conference call and web cast with investors today at 8:00 a.m. ET to discuss this announcement. Call details can be found later in this release.

    About Covidien

    Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2009 revenue of $10.7 billion, Covidien has 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

    About ev3

    Since its founding in 2000, ev3 has been dedicated to developing breakthrough and clinically proven technologies for the endovascular treatment of peripheral vascular and neurovascular diseases. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today -- plaque excision systems, peripheral angioplasty balloons, stents, embolic protection devices, liquid embolics, embolization coils, flow diversion, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at //www.ev3.net.

    CONFERENCE CALL AND WEBCAST

    Covidien will hold a conference call for investors today, beginning at 8:00 a.m. ET. This call can be accessed three ways:

     

    • At Covidien's website: //investor.covidien.com
    • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 800-299-7098. For participants outside the U.S., the dial-in number is 617-801-9715. The access code for all callers is 56418613.
    • Through an audio replay: A replay of the conference call will be available beginning at 9:00 a.m. on June 2, 2010, and ending at 5:00 p.m. on June 8, 2010. The dial-in number for U.S. participants is 888-286-8010. For participants outside the U.S., the replay dial-in number is 617-801-6888. The replay access code for all callers is 46835409.

     

    Supporting materials for the conference call are now available on the Investor Relations section of Covidien's website: //investor.covidien.com

    FORWARD-LOOKING STATEMENTS

    This release contains forward-looking statements that are not historical facts.Covidien and ev3 have identified some of these forward-looking statements with words like "believe," "may," "could," "would," "might," "possible," "will," "should," "expect," "intend," "plan," "anticipate," or "continue," the negative of these words, other terms of similar meaning or the use of future dates.Forward-looking statements in this release include without limitation statements regarding the expected timing of the completion of the transaction and statements regarding the effect of the transaction on Covidien's business and competitive position, statements regarding future innovation and market growth and statements regarding Covidien's future financial performance and financial condition. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties.Risks and uncertainties that could cause results to differ from expectations include: uncertainties as to the timing of the transaction; uncertainties as to how many of ev3's stockholders will tender their shares in the offer; the risk that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, customers, vendors and other business partners; the risk that stockholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; other business effects, including the effects of industry, economic or political conditions outside of Covidien's and ev3's control; transaction costs; actual or contingent liabilities; and other risks and uncertainties discussed in Covidien's and ev3's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections of Covidien's and ev3's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, as well as the tender offer documents to be filed by COV Delaware Corporation, a wholly-owned subsidiary of Covidien, and the Solicitation/Recommendation Statement to be filed by ev3.Neither Covidien nor ev3 undertakes any obligation to update any forward-looking statements as a result of new information, future developments or otherwise, except as expressly required by law.All forward-looking statements in this announcement are qualified in their entirety by this cautionary statement.

    NON-GAAP Financial Information

    This release contains a non-GAAP financial measure. This non-GAAP financial measure, which is used as a measure of Covidien's performance, should be considered in addition to, not as a substitute for, or superior to, measures of Covidien's financial performance prepared in accordance with GAAP. Covidien's non-GAAP measures may be defined differently than similar terms used by other companies, and accordingly, care should be exercised in understanding how Covidien defines its non-GAAP financial measures.

    Specifically, any one-time charge for transaction costs, restructuring, and future payment charges are excluded from the projected earnings per share dilution.

    Covidien management uses this non-GAAP financial measure because it believes it is useful and more meaningful to assess projected earnings per share dilution excluding the transaction-related expenses. This non-GAAP financial measure is also used by Covidien's management in their financial and operating decision-making because management believes it reflects the underlying economics of Covidien's ongoing business in a manner that allows meaningful period-to-period comparisons. Such comparisons may be more meaningful because operating results presented under GAAP may include, from time to time, items that are not necessarily relevant to understand Covidien's business and may, in some cases, be difficult to forecast accurately for future periods. Covidien's management believes that this non-GAAP financial measure provides useful information to investors and others in understanding and evaluating Covidien's current operating performance and future prospects in the same manner as management does if they so choose. Non-GAAP financial measures have limitations, however, because they do not include all items of income and expense that affect Covidien's operations. Covidien's management compensates for this and other limitations by also considering Covidien's financial results as determined in accordance with GAAP.

    IMPORTANT INFORMATION ABOUT THE TENDER OFFER

    This release is neither an offer to purchase nor a solicitation of an offer to sell any securities of ev3 Inc. COV Delaware Corporation ("Purchaser"), an indirect, wholly-owned subsidiary of Covidien, has not commenced the tender offer for the shares of ev3 common stock described in this release.

    Upon commencement of the tender offer, Purchaser will file with the SEC a tender offer statement on Schedule TO and related exhibits, including the offer to purchase, letter of transmittal, and other related documents. Following commencement of the tender offer, ev3 will file with the SEC a tender offer solicitation/recommendation statement on Schedule 14D-9. These documents will contain important information about Covidien, ev3, the transaction and other related matters. Investors and security holders are urged to read each of these documents carefully when they are available.

    Investors and security holders will be able to obtain free copies of the tender offer statement, the tender offer solicitation/recommendation statement and other documents filed with the SEC by Purchaser and ev3 through the web site maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of these documents by contacting:

    Covidien
    Investor Relations
    508-452-4650
    [email protected]

    or

    ev3 Inc.
    Julie Tracy
    Sr. Vice President
    Chief Communications Officer
    949-680-1375
    [email protected]

    Photos/Multimedia Gallery Available: //www.businesswire.com/cgi-bin/mmg.cgi?eid=6310076&lang=en

    SOURCE: Covidien plc

    Covidien
    Eric Kraus, 508-261-8305
    Senior Vice President
    Corporate Communications
    [email protected]
    Coleman Lannum, CFA, 508-452-4343
    Vice President
    Investor Relations
    [email protected]
    Bruce Farmer, 508-452-4372
    Vice President
    Public Relations
    [email protected]
    Brian Nameth, 508-452-4363
    Director
    Investor Relations
    [email protected]
    or
    ev3
    Julie Tracy, 949-680-1375
    Sr. Vice President
    Chief Communications Officer
    [email protected]

    (来源: Covidien )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 喝了6瓶劲酒和1斤白酒 男子手持钢锯在重庆西站撒泼遭控制 2019-06-01
  • 18号辽宁快乐12选5走势图 快乐双彩什么玩 河北快三和值遗漏 福彩3d和值走势图双彩网 双色球分布图中彩网 北京cba 香港正版两肖两码中特 中彩手彩票官网 双色球香港六合彩 七乐彩2011走势图南方版 必赢彩票什么情况 310体育直播 2019十二生肖灵码图 河南省22选五开奖结果 河南快赢481最近200期